The Diagnostic Value Of C Reactive Protein, Procalcitonin And Interleukin- 6 In Pulmonary Bacterial Infections And Guide Of Antibiotics Application

Objective: To evaluate the role of C reactive protein, procalcitonin and interleukin- 6 in the lungs of the diagnostic value of bacterial infection, study the change of C reactive protein,procalcitonin and interleukin- 6 in the process of pulmonary bacterial infection treatment,and analyze the immune function change. From the results of C reactive protein、procalcitonin and interleukin-6,we evaluate the progression of the disease, and provide antibiotic treatment evidence to patients.Method: from January 1, 2015 to June 30, 2015,130 cases of patients with pulmonary bacterial infection were chosen as observation group in our hospital, at the same time a random sample of 130 cases were chosen from the hospital physical examination center as a control group. Limosis vein blood was collected for the first time in six hours, and then in the third day,the fifth day, the seventh day. Centrifugal blood was cryopreserved under- 20℃. Then,detect procalcitonin、C reactive protein and interleukin 6 with cryopreserved blood, whole blood for the ratio of CD4+/CD8+. At the same time using simplified lung infection rating scale(table 1) to rate on the degree of pulmonary infection in patients(the heavier lung infection the higher score of patients), and compare the score with the healthy group.Results: There is significant differences in C reactive protein 、procalcitonin and interleukin 6 between observation group and control group.And the results were gradually decline in observation group on the 3rd day,the5 th day, and the 7th day. There is no significant statistical difference of the ratio of CD4+/CD8+ between observation and control group.Conclusion: C reactive protein、procalcitonin and interleukin- 6 levels in the serum were positively associated with the degree of pulmonary bacterial infections. With the results of C reactive protein、procalcitonin、interleukin- 6and CD4+/ CD8+ and the patient’s clinical symptoms, pulmonary bacterial infections can be diagnosed and the progression of the disease will be evaluated.